Lanean...
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
Evolocumab is a PCSK9 inhibitor which is administered subcutaneously, and when added to statin therapy it has been shown to cause a significant incremental LDL-C reduction, leading to a reduction of cardiovascular risk. Evolocumab has a favorable side effect profile, and its self-administration at h...
Gorde:
| Argitaratua izan da: | Patient Prefer Adherence |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6214408/ https://ncbi.nlm.nih.gov/pubmed/30464416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S149423 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|